Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit (Tables)

v3.20.1
Stockholders' Deficit (Tables)
9 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Schedule of Stock Warrant Activity

Warrant detail for the nine months ended March 31, 2020 is reflected below:

 

   

Number of

Warrants

   

Weighted

Average

Exercise

Price Per

Warrant

   

Remaining

Contract

Term (#

years)

 
Warrants outstanding and exercisable at June 30, 2019     8,333     $ 20.00       0.25  
Warrants issued     -     $ -       -  
Warrants exercised     -     $ -       -  
Warrants forfeited     (8,333 )   $ 20.00       -  
Warrants outstanding and exercisable at March 31, 2020     -     $ -       -  

 

Warrant detail for the nine months ended March 31, 2019 is reflected below:

 

   

Number of

Warrants

   

Weighted

Average

Exercise

Price Per

Warrant

   

Remaining

Contract

Term (#

years)

 
Warrants outstanding and exercisable at June 30, 2018     174,079     $ 20.30       0.74  
Warrants issued     -     $ -       -  
Warrants exercised     -     $ -       -  
Warrants exchanged     (165,746 )   $ 20.30       -  
Warrants forfeited     -     $ -       -  
Warrants outstanding and exercisable at March 31, 2019     8,333     $ 20.00       0.50  

Schedule of Stock Options Activity

Activity in stock options during the nine months ended March 31, 2020, and related balances outstanding as of that date are reflected below:

 

    Number of Shares     Weighted Average Exercise
Price
    Weighted Average Remaining Contract Term (# years)  
Outstanding at June 30, 2019     580,171     $ 11.05       8.59  
Granted     15,792     $ 8.87          
Exercised     (5,249 )   $ 4.68          
Forfeited and cancelled     (8,718 )   $ 12.56          
Outstanding at March 31, 2020     581,996     $ 11.02       7.87  
Exercisable at March 31, 2020     414,720     $ 10.65       7.53  

 

Activity in stock options during the nine months ended March 31, 2019, and related balances outstanding as of that date are reflected below:

 

    Number of Shares     Weighted Average Exercise
Price
    Weighted Average Remaining Contract Term (# years)  
Outstanding at June 30, 2018     354,447     $ 8.30       8.87  
Granted     247,896     $ 14.40          
Exercised     -     $ -          
Forfeited and cancelled     (18,366 )   $ 4.60          
Outstanding at March 31, 2019     583,977     $ 11.00       8.78  
Exercisable at March 31, 2019     266,919     $ 9.60       7.98  

Schedule of Stock-Based Compensation Expenses

The Company allocated stock-based compensation expense included in the condensed consolidated statements of operations for employee option grants and non-employee option grants as follows:

 

    For the Three Months Ended March 31     For the Nine Months Ended March 31,  
    2020     2019     2020     2019  
Research and development   $ 54,000     $ 225,000     $ 162,000     $ 256,000  
General and administration     402,000       861,000       1,194,000       1,236,000  
Total stock-based compensation expense   $ 456,000     $ 1,086,000     $ 1,356,000     $ 1,492,000  

Schedule of Fair Value Assumptions of Stock Options

The fair value of stock options was measured at the grant date using the assumptions (annualized percentages) in the table below:

 

Nine months ended March 31,   2020     2019  
Expected volatility     100.60 %     111 %
Risk free interest rate     1.73 %     2.10 %
Forfeiture rate     20.0 %     20.0 %
Dividend yield     0 %     0 %
Expected term (years)     5.56       5